Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive new study aims to unlock secrets of rare blood cancers

NCT ID NCT07362225

Recruiting now Knowledge-focused Sponsor: MPN Research Foundation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track symptoms, treatments, and how the disease progresses. The goal is to find patterns that could lead to better care and future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this registry could reveal patterns that help doctors predict disease progression and improve treatment guidelines for MPN patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. Results depend on data quality and may take years to yield actionable insights.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE MPN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera acute myeloid leukemia with multilineage dysplasia blast phase chronic myelogenous leukemia, BCR-ABL1 positive bone marrow neoplasm cellular phase chronic idiopathic myelofibrosis Disease Progression essential thrombocythemia hematopoietic and lymphoid system neoplasm leukemia, myeloid, accelerated-phase mycosis fungoides myelodysplastic/myeloproliferative neoplasm myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm myeloproliferative neoplasm, unclassifiable primary myelofibrosis Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACCELERATED PHASE MPN ACCELERATED PHASE MYELOPROLIFERATIVE NEOPLASM AGNOGENIC MYELOID METAPLASIA BLAST PHASE MPN BLAST PHASE MYELOPROLIFERATIVE NEOPLASM CHRONIC IDIOPATHIC MYELOFIBROSIS ESSENTIAL THROMBOCYTHEMIA (ET) ET (ESSENTIAL THROMBOCYTHEMIA) IDIOPATHIC MYELOFIBROSIS MDS/MPN CROSSOVER SYNDROMES MF MPN MPN (MYELOPROLIFERATIVE NEOPLASMS) MPN-ASSOCIATED MYELOFIBROSIS MYELOFIBROSIS MYELOFIBROSIS (PMF) MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH HIGH MOLECULAR RISK MUTATIONS MYELOFIBROSIS, POST ET MYELOFIBROSIS, POST PV MYELOFIBROSIS, PRIMARY MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS MYELOFIBROSIS，MF MYELOPROLIFERATIVE DISORDER MYELOPROLIFERATIVE DISORDERS MYELOPROLIFERATIVE DISORDERS (MPD) MYELOPROLIFERATIVE NEOPLASM WITH 10% BLASTS OR HIGHER MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASMS MYELOPROLIFERATIVE NEOPLASMS (MPNS) POLYCYTHEMIA VERA POLYCYTHEMIA VERA (PV) POST POLYCYTHEMIA VERA MYELOFIBROSIS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) POST-ET MF POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) POST-PV MF PRE-FIBROTIC MYELOFIBROSIS PRIMARY MYELOFIBROSIS (MF) PRIMARY MYELOFIBROSIS (PMF) SECONDARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS (POST-POLYCYTHEMIA VERA MYELOFIBROSIS, POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS) SECONDARY MYELOFIBROSIS IN MYELOPROLIFERATIVE DISEASE THROMBOCYTHEMIA ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) THROMBOCYTHEMIA, HEMORRHAGIC

Contacts and locations

Locations

  • MPN Research Foundation

    RECRUITING

    Chicago, Illinois, 60654, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.